Afatinib Route Development: Market Applications of Two Chiral Quinazoline Intermediates
Explore how CAS 314771-88-5 and 314771-76-1 support afatinib route research, process development and quality-focused sourcing.
As oncology programs mature from discovery into route evaluation, buyers increasingly need well-defined heterocyclic intermediates that can shorten process-development timelines. Rlavie supplies CAS 314771-88-5 and CAS 314771-76-1 for qualified research, route comparison and process-development projects involving afatinib-related chemistry.
Where these products create value
CAS 314771-88-5 is the nitro precursor and CAS 314771-76-1 the corresponding amino quinazoline described in public synthetic literature. Their practical value lies in enabling nitro-reduction studies, downstream coupling development, impurity mapping and analytical-method work without rebuilding every upstream step.
Market drivers and outlook
Demand is supported by continuing kinase-inhibitor research, lifecycle process optimization and the need for robust alternative routes. The opportunity is broader than one commercial medicine: the quinazoline platform remains relevant to medicinal chemistry and process teams working on targeted small molecules. Buyers will increasingly differentiate suppliers by stereochemical identity, related-substance control, residual-metal strategy and documentation quality.
How Rlavie supports projects
Rlavie can discuss specification alignment, batch documentation, packaging, lead time and custom-synthesis requirements. Product availability does not imply participation in any approved-drug supply chain; it provides a practical starting point for customer-controlled research and development.
Products to evaluate for your project
N-(3-Chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]-4-quinazolinaMine (CAS 314771-88-5); (S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine (CAS 314771-76-1).
Related Rlavie products
- N-(3-Chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]-4-quinazolinaMine — CAS 314771-88-5
- (S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine — CAS 314771-76-1
Contact Rlavie for specifications and a quotation, or discuss custom synthesis.
Resources and references
- US9845315B2: public afatinib synthesis and nitro-to-amino sequence
- EMA Giotrif: regulatory context
- ICH Q11: drug-substance development and control strategy
Links and product identities reviewed on 16 September 2026. Application outlook is qualitative; availability, specifications and suitability are confirmed by project enquiry.